Subscribe
shutterstock_1569359980_sundry_photography
Sundry Photography / Shutterstock.com
14 May 2020GenericsRory O'Neill

Gilead agrees 127-country remdesivir licence with generic makers

Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Junshi licenses COVID-19 antibody tech from Lonza
14 July 2020   China’s Junshi Biosciences has licensed technology to produce an antibody against COVID-19 from Swiss biotechnology firm Lonza.
Big Pharma
Gilead continues oncology expansion with Tizona deal
22 July 2020   Gilead Sciences is continuing its expansion into the field of cancer therapeutics with the purchase of a 49.9% stake in California-based biotechnology company Tizona.
Big Pharma
Roche secures rights to potential COVID-19 drug
22 October 2020   Swiss pharmaceutical company Roche will pay $350 million for the rights to develop and distribute an investigational COVID-19 antiviral outside of the US.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Biotechnology
Junshi licenses COVID-19 antibody tech from Lonza
14 July 2020   China’s Junshi Biosciences has licensed technology to produce an antibody against COVID-19 from Swiss biotechnology firm Lonza.
Big Pharma
Gilead continues oncology expansion with Tizona deal
22 July 2020   Gilead Sciences is continuing its expansion into the field of cancer therapeutics with the purchase of a 49.9% stake in California-based biotechnology company Tizona.
Big Pharma
Roche secures rights to potential COVID-19 drug
22 October 2020   Swiss pharmaceutical company Roche will pay $350 million for the rights to develop and distribute an investigational COVID-19 antiviral outside of the US.

More on this story

Biotechnology
Junshi licenses COVID-19 antibody tech from Lonza
14 July 2020   China’s Junshi Biosciences has licensed technology to produce an antibody against COVID-19 from Swiss biotechnology firm Lonza.
Big Pharma
Gilead continues oncology expansion with Tizona deal
22 July 2020   Gilead Sciences is continuing its expansion into the field of cancer therapeutics with the purchase of a 49.9% stake in California-based biotechnology company Tizona.
Big Pharma
Roche secures rights to potential COVID-19 drug
22 October 2020   Swiss pharmaceutical company Roche will pay $350 million for the rights to develop and distribute an investigational COVID-19 antiviral outside of the US.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility